Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma.

eLife - 30 Nov 2020

Pal Ananya, Leung Jia Yu, Ang Gareth Chin Khye, Rao Vinay Kumar, Pignata Luca, Lim Huey Jin, Hebrard Maxime, Chang Kenneth Te, Lee Victor Km, Guccione Ernesto, Taneja Reshma

Abstract excerpt

Wnt signaling is downregulated in embryonal rhabdomyosarcoma (ERMS) and contributes to the block of differentiation. Epigenetic mechanisms leading to its suppression are unknown and could pave the way toward novel therapeutic modalities. We demonstrate that EHMT2 suppresses canonical Wnt signaling by activating expression of the Wnt antagonist DKK1. Inhibition of EHMT2 expression or activity in human ERMS cell...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Dimethyl Sulfoxide
Share to Histocompatibility Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Histone-Lysine N-Methyltransferase

Share to Puromycin

Share to Pyrazines

Share to Pyridines

Share to Rhabdomyosarcoma, Embryonal

Share to Wnt Signaling Pathway

Source

Open in PubMed Open full text

Identifiers

PMID: 33252038
DOI: 10.7554/eLife.57683
PMCID: PMC7728445

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma.PMID 33252038Read ↗

Pharmacological inhibition of EZH2 as a promising differentiation therapy in embryonal RMSSemantic proximity Read ↗

Histone Deacetylase Inhibitors Antagonize Distinct Pathways to Suppress Tumorigenesis of Embryonal RhabdomyosarcomaSemantic proximity Read ↗

MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in embryonal rhabdomyosarcomaSemantic proximity Read ↗

Dependence of PAX3-FOXO1 chromatin occupancy on ETS1 at important disease-promoting genes exposes new targetable vulnerability in Fusion-Positive RhabdomyosarcomaSemantic proximity Read ↗

Inhibition of the Notch-Hey1 Axis Blocks Embryonal Rhabdomyosarcoma TumorigenesisSemantic proximity Read ↗

Glycogen synthase kinase 3 inhibitors induce the canonical WNT/β-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcomaSemantic proximity Read ↗

Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in RhabdomyosarcomaSemantic proximity Read ↗

Epigenetic targeting of PGBD5-dependent DNA damage in SMARCB1-deficient sarcomasSemantic proximity Read ↗

Epigenetic Drugs Can Stimulate Metastasis through Enhanced Expression of the Pro-Metastatic Ezrin GeneSemantic proximity Read ↗

DNMT3B in vitro knocking-down is able to reverse embryonal rhabdomyosarcoma cell phenotype through inhibition of proliferation and induction of myogenic differentiation.Semantic proximity Read ↗

PRC2-Mediated Transcriptomic Alterations at the Embryonic Stage Govern Tumorigenesis and Clinical Outcome in MYCN-Driven NeuroblastomaSemantic proximity Read ↗

RUNX2 inhibition disrupts a PAX3::FOXO1-RUNX2 feed-forward loop and dismantles oncogenic gene programs in fusion-positive rhabdomyosarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.